Effectiveness of an Optimal-Massive Intervention in Older Patients With Dysphagia (OMI)
Primary Purpose
Swallowing Disorder, Oropharyngeal Dysphagia, Respiratory Infection
Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Optimal-Massive Intervention
Control (standard clinical practice)
Sponsored by
About this trial
This is an interventional prevention trial for Swallowing Disorder
Eligibility Criteria
Inclusion Criteria:
- Patients aged 70 years or older.
- Diagnosed oropharyngeal dysphagia (signs of impaired efficacy and/or safety of swallow assessed with the V-VST).
- Giving written informed consent. In case of dementia or incapacitation, given consent by the nearest relative, main caregiver or legal representative.
Exclusion Criteria:
- Impaired safety of swallow with 5mL at high viscosity (800 mPa•s for NC).
- Severe dementia (Pfeiffer >6).
- Life expectancy less than 6 months.
- High functional dependence (Barthel index <40, preadmission).
- Dysphagia caused by anatomical alterations or by head and neck cancer or its treatment.
- Patients going to nursing home or long-term care at discharge.
- Participation in any other studies involving investigational or marketed products within four weeks prior to start of the study.
- Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.
- Patients with symptoms suggestive of COVID-19 or confirmed COVID-19.
Sites / Locations
- Consorci Sanitari del Maresme (Hospital de Mataró)Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
OMI intervention
Control intervention (standard clinical practice)
Arm Description
Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
Outcomes
Primary Outcome Measures
Respiratory infections incidence.
Respiratory infections incidence (includes LRTI, pneumonia and exacerbations of COPD): all new episodes of respiratory infections recorded in the clinical history or in the reports presented by the patient will be recorded. LRTI: presence of at least 2 of the following symptoms without other cause to explain them: fever, cough, purulent expectoration, rhonchi or wheezing. Pneumonia: performing 1 or more radiographic tests with new condensation, fever or leukopenia or leukocytosis and at least: cough, purulent expectoration, dyspnea, tachypnea, suggestive auscultation or worsening of gas exchange. COPD exacerbation: acute exacerbation of COPD is a sudden worsening of COPD symptoms (shortness of breath, quantity and color of phlegm) that typically lasts for several days. It may be triggered by an infection with bacteria or viruses or by environmental pollutants.
Secondary Outcome Measures
Mortality
Mortality: the date and reason for death will be recorded (hospitalization, 1, 3 and 6 months).
General readmissions and readmissions for respiratory infections
General readmissions and readmissions for respiratory infections (1, 3 and 6 months): LRTI, pneumonia and exacerbations of COPD: the reason for admission will be that stated in the hospital database (CMBDAH) according to CIM-10. The information source of the readmissions will be the registration of hospital discharges that is integrated into the hospital information system and that includes the CIM-10 codes of the main and secondary diagnoses of the episode that caused the admission, the date of admission and discharge and the days of hospitalization. Readmissions from pneumonia (codes CIM-10): J13, J18.1, J15.1, J14, J15.4, J15.211, J15.5, A48.1, J15.8, J18.0, J18.8, J69.0; readmissions for LRTI (no pneumonic): J20.0 - J20.9, J10.1, J11.1, J41.8, J44.1 and J44.0. Readmissions from exacerbation of COPD: J441.
Nutritional status (MNA)
Mini-nutritional assessment form (MNA) (hospitalization, 1, 3 and 6 months).
Nutritional status (Anthropometric measures)
Heigh in cm (hospitalization, 1, 3 and 6 months).
Nutritional status (Anthropometric measures2)
Weight in kg (hospitalization, 1, 3 and 6 months).
Nutritional status (Biochemical parameters)
Biochemical parameters from blood analysis (hospitalization, 3 and 6 months).
Hydration status (bioimpedance)
Hydration status: we will register total body water and intracellular water with bioimpedance (hospitalization, 1, 3 and 6 months).
Quality of life of patients during the study period
Quality of life: EQ-5D questionnaire will be used (hospitalization, 1, 3 and 6 months).
Functional status
Functional status: we will use the Barthel Index (hospitalization, 1, 3 and 6 months).
Oral Hygiene
Oral Hygiene: the OHI-S (simplified oroal hygiene index) will be collected (hospitalization, 1, 3 and 6 months).
Dysphagia severity
Severity of dysphagia: according to the different viscosities that patients will be able to swallow and with the Functional Oral Intake Scale (V-VST/FOIS) (hospitalization, 1, 3 and 6 months).
Full Information
NCT ID
NCT04581486
First Posted
September 15, 2020
Last Updated
July 12, 2022
Sponsor
Hospital de Mataró
Collaborators
Nutricia Research
1. Study Identification
Unique Protocol Identification Number
NCT04581486
Brief Title
Effectiveness of an Optimal-Massive Intervention in Older Patients With Dysphagia
Acronym
OMI
Official Title
Evaluation of the Effectiveness of an Optimal-Massive Intervention in Older Patients With Oropharyngeal Dysphagia
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 6, 2021 (Actual)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital de Mataró
Collaborators
Nutricia Research
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to evaluate the efficacy of an optimal-massive intervention (OMI) based on increasing shear viscosity of fluids, nutritional support with oral nutritional supplements (ONS) and triple adaptation of food (rheological and textural, caloric and protein and organoleptic) and oral hygiene improvement on the incidence of respiratory infections in older patients with OD. We have designed a randomized clinical trial, with two parallel arms and 6 months follow-up. The study population will be constituted by older patients of 70 years or more with OD hospitalized at Hospital de Mataró by an acute process that will be identified by using the volume-viscosity swallow clinical test. We will consecutively recruit 500 subjects during admission (Geriatrics, Internal medicine, etc.) at the Hospital de Mataró. Patients included will be randomly assigned to one of both interventional groups: a) study intervention: multifactorial intervention based on fluid viscosity adaptation (with a xanthan gum thickener -> Nutilis Clear®), nutritional support with a triple adaptation of food (texture, caloric and protein content, organoleptic) + pre-thickened ONS and evaluation and treatment of oral hygiene (tooth brushing + antiseptic mouthwashes + professional dental cleaning), or b) control intervention: standard clinical practice (fluid adaptation with Nutilis Powder and simple texture adaptation for solids). Main outcome measures: respiratory infection incidence during the 6-month period follow-up. Secondary outcomes: mortality at 6 months, general hospital readmissions and readmissions due to respiratory infections, nutritional status, hydration status, quality of life, functional status, oral hygiene and dysphagia severity and its relationship with other study variables.
Detailed Description
DESIGN
- Study design: Randomized controlled clinical trial with two parallel arms and 6 months follow-up.
AIMS
Primary aim: To evaluate the effect of a rheological, nutritional and oral hygiene intervention (OMI) on the incidence of respiratory infections including lower respiratory tract infections -LRTI-, pneumonia and chronic obstructive pulmonary disease (COPD) infectious exacerbations in older patients with OD at 6 months follow-up.
Secondary aims: to evaluate the effect at 1, 3 and 6 months of this intervention on:
Mortality.
General hospital readmission and hospital readmission due to respiratory infections.
Nutritional status according to the MNA, anthropometrical measures and biochemical markers.
Hydration status according to bioimpedance.
Quality of life according to the EQ-5D.
Functional status according to Barthel index.
Oral hygiene status according to the simplified oral hygiene index (OHI-S).
Other aims:
- To evaluate the effect at 1, 3 and 6 months of this intervention on:
Swallowing function according to the V-VST.
Rate of institutionalization.
Compliance with the treatments (thickeners, ONS, diets and oral health).
Palatability and acceptability of diets.
To evaluate the relationship between severity of dysphagia (V-VST / FOIS), nutritional status, oral hygiene and the incidence of respiratory infections (LRTI, pneumonia and/or COPD exacerbations).
STUDY POPULATION
- Study subjects: 500 older patients with OD admitted to Hospital de Mataró for acute conditions (internal medicine, cardiology, pneumology, neurology, geriatric wards, etc). Number of subjects necessary: 500 (G1: 250; G2: 250): Accepting an α risk of 0.05 and a β risk of 0.2 in a bilateral contrast, 244 subjects in each group are required to detect as statistically significant difference in the percentage of patients with LRTI at six months that for the control group is expected to be 20 % and for the intervention group of 10% (reduction by half).A tracking loss rate of 20% has been assumed and the required number of subjects (244) in each group already includes the dropout rate. Investigators will intend to recruit a total sample of 500* individuals, 250 in each intervention branch.
SAFETY - Safety and tolerance parameters: Incidence, frequency, seriousness, severity and relatedness of adverse events or serious adverse events.
STUDY GROUPS AND INTERVENTION
- Study groups: there will be 2 groups of patients: G1 - study intervention, 250 patients; G2 - control intervention, 250 patients.
- Study interventions:there will be 2 interventions: G1) study intervention: multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning); G2) control intervention: standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®)).
STATISTICAL ANALYSIS
- Statistical analysis: the primary outcome will be the occurrence of the respiratory infections during the follow-up period (number of events/100 patients-year) and will be mainly analyzed with the Poisson regression.
Qualitative data will be presented as relative and absolute frequencies and analyzed by the Fisher's exact test or the Chi-square test. Volume and viscosity levels (V-VST) will be compared between them by applying the McNemar's test. Continuous data will be presented as mean±standard deviation (SD) and compared with the T-test (intergroup comparisons) or Paired T-test (intragroup comparisons). For those variables that will not follow a normal distribution, the nonparametric Mann-Whitney U-test (intergroup comparisons), the Wilcoxon-paired test (intragroup comparisons) or the Kruskal-Wallis' test for multiple comparisons with Dunn's multiple comparison test will be used. Survival curves will be used to evaluate 6-month mortality after discharge. The primary analysis will be performed on the ITT population. Note: primary analysis is on number of events at 6 months follow-up, to simplify sample size considerations are based on percentage of patients with LRTI at 6 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Swallowing Disorder, Oropharyngeal Dysphagia, Respiratory Infection, Malnutrition, Dehydration, Oral Disease
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
OMI intervention
Arm Type
Experimental
Arm Description
Multimodal intervention based on optimal fluid viscosity adaptation (with Nutilis Clear®), optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning)
Arm Title
Control intervention (standard clinical practice)
Arm Type
Other
Arm Description
Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
Intervention Type
Other
Intervention Name(s)
Optimal-Massive Intervention
Intervention Description
Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
Intervention Type
Other
Intervention Name(s)
Control (standard clinical practice)
Intervention Description
Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
Primary Outcome Measure Information:
Title
Respiratory infections incidence.
Description
Respiratory infections incidence (includes LRTI, pneumonia and exacerbations of COPD): all new episodes of respiratory infections recorded in the clinical history or in the reports presented by the patient will be recorded. LRTI: presence of at least 2 of the following symptoms without other cause to explain them: fever, cough, purulent expectoration, rhonchi or wheezing. Pneumonia: performing 1 or more radiographic tests with new condensation, fever or leukopenia or leukocytosis and at least: cough, purulent expectoration, dyspnea, tachypnea, suggestive auscultation or worsening of gas exchange. COPD exacerbation: acute exacerbation of COPD is a sudden worsening of COPD symptoms (shortness of breath, quantity and color of phlegm) that typically lasts for several days. It may be triggered by an infection with bacteria or viruses or by environmental pollutants.
Time Frame
From discharge to 6 months follow-up
Secondary Outcome Measure Information:
Title
Mortality
Description
Mortality: the date and reason for death will be recorded (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
General readmissions and readmissions for respiratory infections
Description
General readmissions and readmissions for respiratory infections (1, 3 and 6 months): LRTI, pneumonia and exacerbations of COPD: the reason for admission will be that stated in the hospital database (CMBDAH) according to CIM-10. The information source of the readmissions will be the registration of hospital discharges that is integrated into the hospital information system and that includes the CIM-10 codes of the main and secondary diagnoses of the episode that caused the admission, the date of admission and discharge and the days of hospitalization. Readmissions from pneumonia (codes CIM-10): J13, J18.1, J15.1, J14, J15.4, J15.211, J15.5, A48.1, J15.8, J18.0, J18.8, J69.0; readmissions for LRTI (no pneumonic): J20.0 - J20.9, J10.1, J11.1, J41.8, J44.1 and J44.0. Readmissions from exacerbation of COPD: J441.
Time Frame
Through study completion, at 1, 3 and 6 months from disharge.
Title
Nutritional status (MNA)
Description
Mini-nutritional assessment form (MNA) (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Nutritional status (Anthropometric measures)
Description
Heigh in cm (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Nutritional status (Anthropometric measures2)
Description
Weight in kg (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Nutritional status (Biochemical parameters)
Description
Biochemical parameters from blood analysis (hospitalization, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Hydration status (bioimpedance)
Description
Hydration status: we will register total body water and intracellular water with bioimpedance (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Quality of life of patients during the study period
Description
Quality of life: EQ-5D questionnaire will be used (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Functional status
Description
Functional status: we will use the Barthel Index (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Oral Hygiene
Description
Oral Hygiene: the OHI-S (simplified oroal hygiene index) will be collected (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Dysphagia severity
Description
Severity of dysphagia: according to the different viscosities that patients will be able to swallow and with the Functional Oral Intake Scale (V-VST/FOIS) (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Other Pre-specified Outcome Measures:
Title
Sociodemographics
Description
Sociodemographic characteristics of the study population.
Time Frame
Baseline
Title
Swallowing function (V-VST)
Description
Swallowing function (V-VST) (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Institutionalization
Description
Rate of institutionalization (1, 3 and 6 months).
Time Frame
Through study completion, at 1, 3 and 6 months from disharge.
Title
Pharmacological treatment
Description
Drugs taken by the patient.
Time Frame
Baseline
Title
Geriatric syndromes
Description
Geriatric syndromes
Time Frame
Baseline
Title
Frailty 1
Description
Fried criteria (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Frailty 2
Description
Edmonton frail scale (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Toxic habits
Description
Smoking and alcohol consumption
Time Frame
Baseline
Title
Compliance
Description
Compliance with the recommendations of the study intervention (adaptations of fluid, prescribed diets and oral hygiene) (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Palatability
Description
Palatability of the intervention products will be measured with the 5-point facial hedonic scale (hospitalization, 1, 3 and 6 months).
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
Title
Acceptability
Description
Acceptability of the dietes will be measured with the Food Action Rating Scale (hospitalization, 1, 3 and 6 months)
Time Frame
Through study completion, during hospitalization, and at 1, 3 and 6 months from disharge.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged 70 years or older.
Diagnosed oropharyngeal dysphagia (signs of impaired efficacy and/or safety of swallow assessed with the V-VST).
Giving written informed consent. In case of dementia or incapacitation, given consent by the nearest relative, main caregiver or legal representative.
Exclusion Criteria:
Impaired safety of swallow with 5mL at high viscosity (800 mPa•s for NC).
Severe dementia (Pfeiffer >6).
Life expectancy less than 6 months.
High functional dependence (Barthel index <40, preadmission).
Dysphagia caused by anatomical alterations or by head and neck cancer or its treatment.
Patients going to nursing home or long-term care at discharge.
Participation in any other studies involving investigational or marketed products within four weeks prior to start of the study.
Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements.
Patients with symptoms suggestive of COVID-19 or confirmed COVID-19.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pere Clavé, MD, PhD
Phone
+34937417700
Ext
1046
Email
pere.clave@ciberehd.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pere Clavé, MD, PhD
Organizational Affiliation
Director of Research and Academic Development at CSdM
Official's Role
Principal Investigator
Facility Information:
Facility Name
Consorci Sanitari del Maresme (Hospital de Mataró)
City
Mataró
State/Province
Barcelona
ZIP/Postal Code
08301
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pere Clavé, MD, PhD
Phone
+34937417700
Ext
1046
Email
pere.clave@ciberehd.org
First Name & Middle Initial & Last Name & Degree
Omar Ortega, MSc, PhD
First Name & Middle Initial & Last Name & Degree
Alberto Martín, Nurse
First Name & Middle Initial & Last Name & Degree
Alícia Costa, Dietist
First Name & Middle Initial & Last Name & Degree
Weslania Nascimento, SLP, PhD
First Name & Middle Initial & Last Name & Degree
Stephanie Riera, SLP
First Name & Middle Initial & Last Name & Degree
Viridiana Arreola, SLP
First Name & Middle Initial & Last Name & Degree
Paula Viñas, Dietist
First Name & Middle Initial & Last Name & Degree
Claudia Alarcón, Dietist
First Name & Middle Initial & Last Name & Degree
Romina Escobar, Dietist
First Name & Middle Initial & Last Name & Degree
Pere Clavé, MD, PhD
12. IPD Sharing Statement
Citations:
PubMed Identifier
29806864
Citation
Martin A, Ortega O, Roca M, Arus M, Clave P. Effect of A Minimal-Massive Intervention in Hospitalized Older Patients with Oropharyngeal Dysphagia: A Proof of Concept Study. J Nutr Health Aging. 2018;22(6):739-747. doi: 10.1007/s12603-018-1043-3.
Results Reference
result
PubMed Identifier
28412164
Citation
Ortega O, Martin A, Clave P. Diagnosis and Management of Oropharyngeal Dysphagia Among Older Persons, State of the Art. J Am Med Dir Assoc. 2017 Jul 1;18(7):576-582. doi: 10.1016/j.jamda.2017.02.015. Epub 2017 Apr 12.
Results Reference
result
Learn more about this trial
Effectiveness of an Optimal-Massive Intervention in Older Patients With Dysphagia
We'll reach out to this number within 24 hrs